Daniil Gataulin
Stock Analyst at Chardan Capital
(4.65)
# 197
Out of 5,152 analysts
125
Total ratings
55.75%
Success rate
35.82%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Daniil Gataulin
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| CRVO CervoMed | Maintains: Buy | $15 | $4.02 | +273.13% | 8 | Mar 5, 2026 | |
| EYPT EyePoint | Maintains: Buy | $27 → $29 | $18.00 | +61.11% | 13 | Mar 4, 2026 | |
| QURE uniQure | Maintains: Buy | $53 → $16 | $9.04 | +76.99% | 12 | Mar 3, 2026 | |
| OTLK Outlook Therapeutics | Maintains: Neutral | $1 | $0.44 | +128.05% | 12 | Feb 18, 2026 | |
| OCUL Ocular Therapeutix | Maintains: Buy | $21 | $11.04 | +90.22% | 5 | Feb 18, 2026 | |
| RGNX REGENXBIO | Maintains: Buy | $52 → $50 | $9.14 | +447.05% | 16 | Feb 10, 2026 | |
| OCGN Ocugen | Maintains: Buy | $7 | $1.96 | +257.14% | 15 | Jan 20, 2026 | |
| ANNX Annexon | Initiates: Buy | $16 | $5.59 | +186.23% | 1 | Dec 23, 2025 | |
| KLRS Kalaris Therapeutics | Initiates: Buy | $19 | $9.08 | +109.25% | 1 | Dec 23, 2025 | |
| FBRX Forte Biosciences | Maintains: Buy | $61 | $31.76 | +92.07% | 7 | Nov 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $14 | $26.84 | -47.84% | 4 | Nov 17, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $10 | $6.99 | +43.06% | 3 | Nov 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $35 | $7.41 | +372.33% | 7 | Nov 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $9 | $4.57 | +96.94% | 3 | Nov 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $51 | $28.60 | +78.32% | 9 | Nov 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $4 | $1.06 | +277.36% | 8 | Aug 8, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $2,200 | $5.02 | +43,724.70% | 1 | Mar 7, 2024 |
CervoMed
Mar 5, 2026
Maintains: Buy
Price Target: $15
Current: $4.02
Upside: +273.13%
EyePoint
Mar 4, 2026
Maintains: Buy
Price Target: $27 → $29
Current: $18.00
Upside: +61.11%
uniQure
Mar 3, 2026
Maintains: Buy
Price Target: $53 → $16
Current: $9.04
Upside: +76.99%
Outlook Therapeutics
Feb 18, 2026
Maintains: Neutral
Price Target: $1
Current: $0.44
Upside: +128.05%
Ocular Therapeutix
Feb 18, 2026
Maintains: Buy
Price Target: $21
Current: $11.04
Upside: +90.22%
REGENXBIO
Feb 10, 2026
Maintains: Buy
Price Target: $52 → $50
Current: $9.14
Upside: +447.05%
Ocugen
Jan 20, 2026
Maintains: Buy
Price Target: $7
Current: $1.96
Upside: +257.14%
Annexon
Dec 23, 2025
Initiates: Buy
Price Target: $16
Current: $5.59
Upside: +186.23%
Kalaris Therapeutics
Dec 23, 2025
Initiates: Buy
Price Target: $19
Current: $9.08
Upside: +109.25%
Forte Biosciences
Nov 17, 2025
Maintains: Buy
Price Target: $61
Current: $31.76
Upside: +92.07%
Nov 17, 2025
Maintains: Neutral
Price Target: $14
Current: $26.84
Upside: -47.84%
Nov 14, 2025
Maintains: Buy
Price Target: $10
Current: $6.99
Upside: +43.06%
Nov 14, 2025
Maintains: Buy
Price Target: $35
Current: $7.41
Upside: +372.33%
Nov 13, 2025
Maintains: Buy
Price Target: $9
Current: $4.57
Upside: +96.94%
Nov 11, 2025
Maintains: Buy
Price Target: $51
Current: $28.60
Upside: +78.32%
Aug 8, 2025
Maintains: Buy
Price Target: $4
Current: $1.06
Upside: +277.36%
Mar 7, 2024
Maintains: Buy
Price Target: $2,200
Current: $5.02
Upside: +43,724.70%